Palisade Bio (NASDAQ:PALI) Releases Earnings Results

Palisade Bio (NASDAQ:PALI) issued its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports.

Palisade Bio Price Performance

NASDAQ PALI traded down $0.02 during trading hours on Tuesday, hitting $1.92. 1,798,672 shares of the company’s stock traded hands, compared to its average volume of 4,292,096. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.86. The company has a market capitalization of $321.45 million, a PE ratio of -0.91 and a beta of 1.52. The firm’s 50-day moving average is $1.98 and its 200-day moving average is $1.92.

Analyst Ratings Changes

PALI has been the subject of several research analyst reports. Wolfe Research initiated coverage on shares of Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target for the company. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They set a “buy” rating and a $7.00 price target for the company. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Palisade Bio currently has a consensus rating of “Moderate Buy” and an average target price of $10.20.

Institutional Trading of Palisade Bio

Several large investors have recently bought and sold shares of PALI. Cetera Investment Advisers purchased a new stake in Palisade Bio during the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in Palisade Bio during the 4th quarter valued at about $26,000. Virtu Financial LLC purchased a new stake in Palisade Bio during the 4th quarter valued at about $28,000. Atom Investors LP purchased a new stake in Palisade Bio during the 4th quarter valued at about $33,000. Finally, WINTON GROUP Ltd purchased a new stake in Palisade Bio during the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.